首页> Molecular cancer therapeutics> FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.

FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.

导出原文传递

翻译打印收藏纠错

第一作者： Andreas,Weiss

第一单位： Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland.

作者： Andreas,Weiss ^[1] ; Flavia,Adler ^[1] ; Alexandra,Buhles ^[1] ; Christelle,Stamm ^[1] ; Robin A,Fairhurst ^[2] ; Michael,Kiffe ^[3] ; Dario,Sterker ^[1] ; Mario,Centeleghe ^[1] ; Markus,Wartmann ^[1] ; Jacqueline,Kinyamu-Akunda ^[4] ; Heiko S,Schadt ^[5] ; Philippe,Couttet ^[5] ; Armin,Wolf ^[5] ; Youzhen,Wang ^[6] ; Patrizia,Barzaghi-Rinaudo ^[1] ; Masato,Murakami ^[1] ; Audrey,Kauffmann ^[1] ; Thomas,Knoepfel ^[2] ; Nicole,Buschmann ^[2] ; Catherine,Leblanc ^[2] ; Robert,Mah ^[2] ; Pascal,Furet ^[2] ; Jutta,Blank ^[7] ; Francesco,Hofmann ^[1] ; William R,Sellers ^[6] ; Diana,Graus Porta ^[8]

作者单位： Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland. ^[1] Novartis Institutes for Biomedical Research, Global Discovery Chemistry, Basel, Switzerland. ^[2] Novartis Institutes for Biomedical Research, PK Sciences, Basel, Switzerland. ^[3] Novartis Institutes for Biomedical Research, Preclinical Safety, East Hanover New Jersey. ^[4] Novartis Institutes for Biomedical Research, Preclinical Safety, Basel, Switzerland. ^[5] Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, Massachusetts. ^[6] Novartis Institutes for Biomedical Research, Chemical Biology and Therapeutics, Basel, Switzerland. ^[7] Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland. diana.graus_porta@novartis.com. ^[8]